June 20, 2024
Dyslexia Treatment Market

Dyslexia Treatment Market Poised to Grow at a Robust Pace Due to Growing Prevalence of Dyslexia Globally

The dyslexia treatment market has been gaining significant prominence over the past few years primarily owing to the increasing incidence of dyslexia worldwide. Dyslexia refers to a specific learning disorder that involves difficulties with reading due to problems with how the brain processes written language. Individuals with dyslexia often have trouble with reading fluently or with accurate comprehension. The symptoms include problems with phonological awareness, spelling, writing skills, and sometimes with numbers. The prevalence of dyslexia varies with some reports estimating that it impacts 5-15% of children. Dyslexia can be treated through therapies, educational programs, and medication in some cases.

The global dyslexia treatment market is estimated to be valued at US$ 11.74 Bn in 2024 and is expected to exhibit a CAGR of 6.4% over the forecast period from 2024 to 2031

The key to dyslexia treatment involves early diagnosis and intervention through various therapies and educational programs that help improve reading, writing, and spelling abilities. Medications are also prescribed in some cases to improve attention, memory, and focus. Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Jubilant Pharma Limited, GSK plc, Eli Lilly and Company, Otsuka Holdings Co., Ltd., Apotex Corporation, Purdue Pharma, Rhodes Pharmaceuticals L.P., Cian Healthcare Pvt. Ltd., Wallace Pharmaceuticals Ltd., The Himmel Group, and Astrazeneca are some of the prominent players operating in the dyslexia treatment market.

Key Takeaways

Key players operating in the Dyslexia Treatment Market Growth are Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Jubilant Pharma Limited, GSK plc, Eli Lilly and Company, Otsuka Holdings Co., Ltd., Apotex Corporation, Purdue Pharma, Rhodes Pharmaceuticals L.P., Cian Healthcare Pvt. Ltd., Wallace Pharmaceuticals Ltd., The Himmel Group, Astrazeneca, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Lupin. These players are focusing on developing advanced therapies and medications for treating dyslexia.

Therapy and educational programs present key growth opportunities for players in the market. Rising awareness regarding early diagnosis and intervention is prompting more individuals to opt for dyslexia-specific treatments.

The increasing focus on expanding access to dyslexia assessment and treatment globally is facilitating the overall market expansion. Players are investing in emerging economies in Asia Pacific and Latin America for tapping the high-growth potential in these regions.

Market Drivers

The growing prevalence of dyslexia due to increasing risk factors like premature birth, low birth weight, family history of dyslexia, etc. is a key factor driving the demand for dyslexia treatment options. According to reports, around 10% of the worldwide population experiences some of the symptoms of dyslexia. As more children and individuals are being diagnosed timely, the number of patients opting for medication, therapies, and programs is surging significantly. This is positively impacting the sales avenues for dyslexia treatment providers. Government support through schemes to spread dyslexia awareness and implementation of dyslexia-inclusive education standards is also fueling the market growth.

PEST Analysis

Political: Government laws and regulations impact the dyslexia treatment market. Governments in different countries have different laws regarding diagnosis and treatment of dyslexia. Government funding support for research also impacts the market.

Economic: Overall economic growth impacts healthcare spending. Economic downturns may decrease spending on dyslexia diagnosis and treatments. Rising disposable incomes also drive the market growth.

Social: Growing social awareness regarding learning disorders like dyslexia is a major driver for the market. Support groups create demand for new treatment options and programs. Social stigma still exists which acts as a restraint.

Technological: Use of technology in treatment and screening is a major trend. Screening software, mobile learning apps, audio books etc. facilitate treatment and learning. Advances in neuroscience also aid development of new drugs and therapies.

The dyslexia treatment market is concentrated in terms of value in developed regions of North America and Europe due to high healthcare spending and awareness in these regions. The United States represents the largest market globally due to presence of supportive government programs and insurance coverage for learning disorders.

The Asia Pacific region is projected to be the fastest growing market during the forecast period due to rising disposable incomes, improving access to healthcare facilities and growing public-private initiatives to spread awareness regarding dyslexia. China and India are expected to drive the growth of APAC dyslexia treatment market supported by increasing diagnosis rates and demand for international standard therapies.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it